Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial.
Saved in:
| Title: | Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial. |
|---|---|
| Authors: | Ryan C; Charles Institute of Dermatology, University College, Dublin, Ireland.; Institute of Dermatologists, Dublin, Ireland., Guenther L; Guenther Dermatology Research Centre, London, ON, Canada., Foley P; Skin Health Institute, Melbourne, VIC, Australia., Weisman J; Medical Dermatology Specialists, Atlanta, GA, USA., Burge RT; Eli Lilly and Company, Indianapolis, IN, USA.; University of Cincinnati, Cincinnati, OH, USA., Gallo G; Eli Lilly and Company, Indianapolis, IN, USA., See K; Eli Lilly and Company, Indianapolis, IN, USA., McKean-Matthews M; Syneos Health, Raleigh, NC, USA., Bertram CC; Eli Lilly and Company, Indianapolis, IN, USA., Merola JF; Harvard Medical School, Boston, MA, USA. |
| Source: | Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2022 Apr; Vol. 36 (4), pp. e277-e279. Date of Electronic Publication: 2021 Dec 04. |
| Publication Type: | Clinical Trial, Phase III; Letter; Randomized Controlled Trial |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-3083 (Electronic) Linking ISSN: 09269959 NLM ISO Abbreviation: J Eur Acad Dermatol Venereol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 34812561 AccessLevel: 2 PubType: Report PubTypeId: report PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Ryan+C%22">Ryan C</searchLink>; Charles Institute of Dermatology, University College, Dublin, Ireland.; Institute of Dermatologists, Dublin, Ireland.<br /><searchLink fieldCode="AU" term="%22Guenther+L%22">Guenther L</searchLink>; Guenther Dermatology Research Centre, London, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Foley+P%22">Foley P</searchLink>; Skin Health Institute, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Weisman+J%22">Weisman J</searchLink>; Medical Dermatology Specialists, Atlanta, GA, USA.<br /><searchLink fieldCode="AU" term="%22Burge+RT%22">Burge RT</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.; University of Cincinnati, Cincinnati, OH, USA.<br /><searchLink fieldCode="AU" term="%22Gallo+G%22">Gallo G</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22See+K%22">See K</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22McKean-Matthews+M%22">McKean-Matthews M</searchLink>; Syneos Health, Raleigh, NC, USA.<br /><searchLink fieldCode="AU" term="%22Bertram+CC%22">Bertram CC</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Merola+JF%22">Merola JF</searchLink>; Harvard Medical School, Boston, MA, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229216037%22">Journal of the European Academy of Dermatology and Venereology : JEADV</searchLink> [J Eur Acad Dermatol Venereol] 2022 Apr; Vol. 36 (4), pp. e277-e279. <i>Date of Electronic Publication: </i>2021 Dec 04. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase III; Letter; Randomized Controlled Trial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9216037 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1468-3083 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209269959%22">09269959 </searchLink><i>NLM ISO Abbreviation: </i>J Eur Acad Dermatol Venereol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34812561 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1111/jdv.17836 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e277 Titles: – TitleFull: Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Ryan C – PersonEntity: Name: NameFull: Guenther L – PersonEntity: Name: NameFull: Foley P – PersonEntity: Name: NameFull: Weisman J – PersonEntity: Name: NameFull: Burge RT – PersonEntity: Name: NameFull: Gallo G – PersonEntity: Name: NameFull: See K – PersonEntity: Name: NameFull: McKean-Matthews M – PersonEntity: Name: NameFull: Bertram CC – PersonEntity: Name: NameFull: Merola JF IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: 2022 Apr Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 1468-3083 Numbering: – Type: volume Value: 36 – Type: issue Value: 4 Titles: – TitleFull: Journal of the European Academy of Dermatology and Venereology : JEADV Type: main |
| ResultId | 1 |
